Feedback / Questions
FPI-2265 - AstraZeneca
FPI-2265: Data from P2/3 AlphaBreak trial (NCT06402331) for mCRPC H2 2025
(AstraZeneca)
-
Feb 6, 2025 -
Q4 & FY2024 Results
P2/3 data
•
Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer
https://www.astrazeneca.com/content/dam/az/PDF/2024/fy/Full-year-and-Q4-2024-results-clinical-trials-appendix.pdf
Feb 6, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious